303 related articles for article (PubMed ID: 16918061)
1. Experience with liposomal amphotericin B at the Hematology-Oncology Department Children's Hospital Salata Medical School, University of Zagreb.
Konja J; Glavas B; Anicić M
Acta Biomed; 2006; 77 Suppl 2():14-6. PubMed ID: 16918061
[TBL] [Abstract][Full Text] [Related]
2. Continuous infusion of amphotericin B deoxycholate: a cost-effective gold standard for therapy of invasive fungal infections?
Schneemann M; Bachli EB
Clin Infect Dis; 2004 Jan; 38(2):303-4; author reply 306-7. PubMed ID: 14699468
[No Abstract] [Full Text] [Related]
3. [Fungal infections in leukemic patients: our experience during 5 years].
Torre MA; Escalante R; López Martín JC; de la Maya MD; Martínez Estéfano E; López Lacomba D; González Aza C
Sangre (Barc); 1996 Oct; 41(5):395-7. PubMed ID: 9026926
[TBL] [Abstract][Full Text] [Related]
4. Increasing incidence of invasive aspergillosis in pediatric hematology oncology patients over the last decade: a retrospective single centre study.
Rubio PM; Sevilla J; González-Vicent M; Lassaletta A; Cuenca-Estrella M; Díaz MA; Riesco S; Madero L
J Pediatr Hematol Oncol; 2009 Sep; 31(9):642-6. PubMed ID: 19684521
[TBL] [Abstract][Full Text] [Related]
5. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
6. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial].
Rieger CT; Dittmer M; Ostermann H
Dtsch Med Wochenschr; 2007 Oct; 132(40):2062-6. PubMed ID: 17899499
[TBL] [Abstract][Full Text] [Related]
7. Potential role of aerosolized amphotericin B formulations in the prevention and adjunctive treatment of invasive fungal infections.
Drew R
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():36-44. PubMed ID: 16713192
[TBL] [Abstract][Full Text] [Related]
8. Successful management of cerebral and pulmonary mucormycosis with liposomal amphotericin B in a 28-year-old woman with acute lymphoblastic leukemia.
Salonen JH
Acta Biomed; 2006; 77 Suppl 2():28-31. PubMed ID: 16918065
[TBL] [Abstract][Full Text] [Related]
9. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
10. New methods for delivery of antifungal agents.
Meunier F
Rev Infect Dis; 1989; 11 Suppl 7():S1605-12. PubMed ID: 2690298
[TBL] [Abstract][Full Text] [Related]
11. [Update on therapy of invasive mycoses in hematology and oncology].
Maschmeyer G; Haas A; Böhme A
Dtsch Med Wochenschr; 2005 Jun; 130(22):1381-4. PubMed ID: 15915381
[No Abstract] [Full Text] [Related]
12. Weekly high-dose liposomal amphotericin B for secondary prophylaxis of invasive fungal disease in immunocompromised children: experience from a pediatric case series.
Ginocchio F; Faraci M; Fioredda F; Moroni C; Caviglia I; Barabino P; Haupt R; Castagnola E
J Chemother; 2012 Aug; 24(4):243-4. PubMed ID: 23040693
[No Abstract] [Full Text] [Related]
13. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.
Garbino J; Markham L; Matulionyte R; Rives V; Lew D
Scand J Infect Dis; 2006; 38(2):110-3. PubMed ID: 16449001
[TBL] [Abstract][Full Text] [Related]
14. Liposomal amphotericin B for the treatment of severe fungal infection.
Michaud D
Dynamics; 2001; 12(1):17-21. PubMed ID: 11982230
[TBL] [Abstract][Full Text] [Related]
15. Treatment of mycotic infections after haemopoietic progenitor cell transplantation with liposomal amphotericin-B.
Krüger WH; Kröger N; Rüssmann B; Renges H; Kabisch H; Zander AR
Bone Marrow Transplant; 1998 Dec; 22 Suppl 4():S10-3. PubMed ID: 9916623
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.
Neofytos D; Horn D; Anaissie E; Steinbach W; Olyaei A; Fishman J; Pfaller M; Chang C; Webster K; Marr K
Clin Infect Dis; 2009 Feb; 48(3):265-73. PubMed ID: 19115967
[TBL] [Abstract][Full Text] [Related]
17. Amphotericin B deoxycholate: no significant advantage of a 24 h over a 6 h infusion schedule.
Altmannsberger P; Holler E; Andreesen R; Krause SW
J Antimicrob Chemother; 2007 Jul; 60(1):180-2. PubMed ID: 17537868
[No Abstract] [Full Text] [Related]
18. Use of liposomal amphotericin B in bone marrow transplant.
Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H
J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256
[TBL] [Abstract][Full Text] [Related]
19. Design of aerosolized amphotericin b formulations for prophylaxis trials among lung transplant recipients.
Perfect JR; Dodds Ashley E; Drew R
Clin Infect Dis; 2004 Oct; 39 Suppl 4():S207-10. PubMed ID: 15546119
[TBL] [Abstract][Full Text] [Related]
20. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
